Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast

Histopathology

Volumn 47, Issue 6, 2005, Pages 617-624

  Vogl, Georgia ^a,b,c   Dietze, O ^a   Hauser Kronberger, C ^a  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Angiogenesis; Cuffing phenomenon; Ductal carcinoma in situ; Human epidermal growth factor 1 and 2; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; ENDOGLIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA UROGASTRONE; ONCOPROTEIN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CARCINOMA IN SITU; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHI-SQUARE DISTRIBUTION; FEMALE; GENES, ERBB-1; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; THYMIDINE PHOSPHORYLASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 28844508366     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02299.x     Document Type: Article

References (26)

1. Bosari S, Lee AK, DeLellis RA et al. Microvessel quantification and prognosis in invasive breast carcinoma. Hum. Pathol. 1992; 23; 755-761.
2. Toi M, Kashitani J, Tominaga T. Tumour angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int. J. Cancer 1993; 55; 371-374.
3. Weidner N, Semple JP, Welch WR et al. Tumour angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 1991; 324; 1-8.
4. Weidner N. Intratumour microvessel density as a prognostic factor in cancer. Am. J. Pathol. 1995: 147; 9-19.
5. Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J. Mamm. Gland Biol. Neoplasia 2001; 6; 393-406.
6. DiGiovanna MP, Chu P, Davison TL et al. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Res. 2002; 62; 6667-6673.
7. Chan KC, Knox WF, Gandhi A et al. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br. J. Surg. 2001; 88; 412-418.
8. Moriya T, Silverberg SG. Intraductal carcinoma (ductal carcinoma in situ) of the breast: a comparison of pure noninvasive tumours with those including different proportions of infiltrating carcinoma. Cancer (Phila) 1994; 74; 2972-2978.
9. Elston CW, Ellis IO. Assessment of histological grade. In Elston CW, Ellis IO, eds. The breast. Vol. 13. Edinburgh, New York: Churchill Livingstone 1998; 356-384.
10. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8; 138-140.
11. Guidi AJ, Fischer L, Harris JR et al. Microvessel density and distribution in ductal carcinoma in situ of the breast. J. Natl Cancer Inst. 1994; 86; 614-619.
12. Engels K, Fox SB, Whitehouse RM et al. Distinct angiogenic patterns are associated with high grade in situ ductal carcinoma of the breast. J. Pathol. 1997; 181; 207-212.
13. Wärnberg F, Nordgren H, Bergkvist L et al. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br. J. Cancer 2001; 85; 869-874.
14. Teo NB, Shoker BS, Jarvis C et al. Angiogenesis and invasive recurrence in ductal carcinoma in situ of the breast. Eur J. Cancer 2003; 39; 38-44.
15. Bobrow LG, Millis RR. The pathology of ductal carcinoma in situ of the breast. Clin. Oncol. (R. Coll. Radiol.) 1995; 7; 232-235.
16. Shoker BS, Jarvis C, Clarke RB et al. Abnormal regulation of the oestrogen receptor in benign breast lesions. J. Clin. Pathol. 2000; 53; 778-783.
17. Holland PA, Knox WF, Potten CS et al. Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast. J. Natl Cancer Inst. 1997; 89; 1059-1065.
18. Lebeau A, Unholzer A, Amann G et al. EGFR, HER-2/neu, cyclin D, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res. Tr. 2003; 79; 187-198.
19. Sainsbury JR, Farndon JR, Needham GK et al. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987; 1; 1398-1402.
20. Robertson KW, Reeves JR, Smith G et al. Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res. 1996; 56; 3823-3830.
21. Baqai T, Shousha S. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast. Histopathology 2003; 42; 440-447.
22. Bundred NJ, Chan K, Anderson NG. Studies of epidermal growth factor receptor inhibition in breast cancer. Endocr. Rel. Cancer 2001; 8; 183-189.
23. Engels K, Fox SB, Whitehouse RM et al. Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast. J. Pathol. 1997; 182; 414-420.
24. Fox SB, Westwood M. Moghaddam A et al. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br. J. Cancer 1996; 73; 275-280.
25. Lee AHS, Dublin EA, Bobrow LG. Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast. J. Pathol. 1999; 187; 285-290.
26. Guidi AJ, Schnitt SJ, Fischer L et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 1997; 80; 1945-1953.